A detailed history of Bayesian Capital Management, LP transactions in Incyte Corp stock. As of the latest transaction made, Bayesian Capital Management, LP holds 18,219 shares of INCY stock, worth $1.38 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
18,219
Previous 14,755 23.48%
Holding current value
$1.38 Million
Previous $894,000 34.68%
% of portfolio
0.14%
Previous 0.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $198,591 - $237,665
3,464 Added 23.48%
18,219 $1.2 Million
Q2 2024

Aug 14, 2024

SELL
$51.18 - $63.75 $179,130 - $223,125
-3,500 Reduced 19.17%
14,755 $894,000
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $1.03 Million - $1.22 Million
18,255 New
18,255 $1.04 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $168,957 - $212,358
-2,553 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$66.02 - $79.71 $168,549 - $203,499
2,553 New
2,553 $203,000
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $240,269 - $352,824
-3,239 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $459,950 - $625,861
-7,280 Reduced 69.21%
3,239 $237,000
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $397,483 - $520,908
5,442 Added 107.19%
10,519 $919,000
Q3 2019

Nov 13, 2019

BUY
$72.82 - $86.52 $369,707 - $439,262
5,077 New
5,077 $377,000
Q1 2018

May 15, 2018

SELL
$83.06 - $100.98 $406,994 - $494,802
-4,900 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$93.56 - $116.6 $278,153 - $346,651
2,973 Added 154.28%
4,900 $464,000
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $210,332 - $266,446
1,927
1,927 $225,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.9B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.